Navigation Links
Pharmacyclics Reports Second Quarter 2014 Results
Date:7/31/2014

SUNNYVALE, Calif., July 31, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended June 30, 2014.

Financial Results for the Six Months and Quarter Ended June 30, 2014 RevenueTotal revenue for the quarter ended June 30, 2014 increased to $113.0 million from $54.7 million for the quarter ended June 30, 2013 primarily due to IMBRUVICA® (ibrutinib) net product revenue of $109.5 million.

Total revenue for the six months ended June 30, 2014 increased to $232.4 million from $57.5 million for the six months ended June 30, 2013 primarily due to net product revenue of $165.7 million from sales of IMBRUVICA.

The quarter ended June 30, 2014 represented the Company's first full quarter of IMBRUVICA sales after receiving approval from the U.S. Food and Drug Administration (FDA) under accelerated approval on February 12, 2014 as a single agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. IMBRUVICA first came to market on November 13, 2013 after receiving approval from the FDA under accelerated approval as a single agent for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Subsequent to June 30, 2014, we announced on July 28, 2014 that the FDA granted IMBRUVICA regular (full) approval for the treatment of patients with CLL who have received at least one prior therapy, and for the treatment of CLL patients with deletion of the short arm of chromosome 17 (del 17p CLL), including treatment naive (frontline) and previously treated del 17p CLL patients. This approval of IMBRUVICA in del 17p CLL triggers $60 million in milestone payments to us under our Agreement with Janssen, which will be recognized as revenue in the third quart
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014
2. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
3. WuXi PharmaTech to Partner with Pharmacyclics
4. Pharmacyclics Reports Third Quarter 2013 Results
5. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
6. Pharmacyclics Reports Second Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
8. Pharmacyclics Reports First Quarter 2013 Results
9. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
10. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
11. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
(Date:10/19/2014)... -- Shire plc (LSE: SHP, NASDAQ: SHPG ... (CFO), has notified the Board of Directors of his decision to ... opportunity as CFO of Severn Trent plc.  James will leave Shire ... a search for a new CFO immediately. Flemming Ornskov, ... and lead a high-quality finance team at Shire. We are very ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... GlySure Limited, developer of in-hospital continuous ... its $10.9 million Series C financing round. GlySure will ... approval in the United States and Europe. ... well as existing investors Amadeus Capital Partners, Chester Investments ...
... -- Global Pharm Holdings Group, Inc. (OTCBB: GPHG) ... integrated pharmaceutical company engaged in the distribution of ... herbal cultivation and sales in China through its ... today announced the appointment of Mr. Kwong Chi ...
Cached Medicine Technology:GlySure Secures $10.9 Million in Series C Financing Round 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
(Date:10/20/2014)... Succeed is proud to announce that they ranked ... the Every Body Walk! campaign by Kaiser Permanente. ... encourages workers to be more active outside of the workplace. ... at the end of September, was a friendly competition between ... Participating companies gave their staff pedometers and each day, ...
(Date:10/20/2014)... 2014 It’s hard to imagine what it’s ... vulnerable children around the world, it’s a reality. And while ... children are forced to walk barefoot on rocky terrain or ... play with their friends. , Buckner International's Shoes ... Radio in October to encourage support for Air1 and ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... 2014 Recently, Top10BestSEOHosting.com has unveiled ... JustHost, GoDaddy and HostMonster are the best VPS ... Private Server) is the method of partitioning a ... which has the appearance and capabilities of running ... the site pays close attention to VPS products ...
(Date:10/19/2014)... stem cell-based research could improve understanding of intestinal diseases ... suggests. Scientists used stem cells to grow "organoids" ... They then transplanted the organoids into mice, creating a ... researchers. "This provides a new way to study ... failure, from genetic disorders appearing at birth to conditions ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... A new approach of imaging discovered by scientists now detects even small smoking-related lung ... track deep into the smokers lungs and its movement - researchers at the University ... images of lungs soft tissues, when helium gas was inhaled prior taking images. ... ...
... anti-quota strike, setting the stage for a face-off with the ... the 19-day long protest can invite contempt proceedings. ... General Body Meetings of the medicos which saw sharp divisions ... has paralysed medical services in the capital., ,'The Youth ...
... incidence of HIV/AIDS is declining in the western Indian state ... , Karnataka and Andhra Pradesh because of the proactive measures ... in the country, especially in the north, it is rising, ... released Tuesday, said that overall two-thirds of the people living ...
... Court of India today asked the students to end their ... if they fail to do so contempt// action can be ... told that their protest had left "patients at the mercy ... are continuing with the strike. If they are over-reaching our ...
... Myanmar into India's northeast has led to a rise in ... says a United Nations study. ,"Drug trafficking across the ... Mizoram and Nagaland occurs with ease. Despite the existence of ... accessible to the local youths of these states," said a ...
... planning to study the effect of cervical cancer on the ... as the biggest study into the psychological and emotional effects ... will be instituted for duration of five years and will ... physical lives of couples. The researchers have said that they ...
Cached Medicine News:Health News:Helium And MRI Scanning Clearly Detects Smoker Lungs – Research Find 2Health News:Supreme Court Warns Medicos of Contempt Action 2Health News:Illegal Drug Trafficking Pose A Great Threat For HIV Epidemic In Northeast 2
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Malis CMC-III Generator provides both coagulation and cutting outputs....
Medicine Products: